All News
Filter News
Found 13,851 articles
-
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is the first FDA-approved tumor-agnostic HER2-targeted therapy authorized for the treatment of solid tumors in adults who have undergone prior systemic treatment.
-
With second-generation antibody-drug conjugates, Eli Lilly, Daiichi Sankyo and others look to reduce toxicity and improve the magnitude and duration of response.
-
2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.
-
Cancer Immunotherapy Market Size to Increase USD 280.11 BN by 2033
4/8/2024
According to Vision Research Reports, the global cancer immunotherapy market size was estimated at USD 125.73 billion in 2023 and it is projected to increase USD 280.11 billion by 2033 with a CAGR of 8.34% from 2024 to 2033.
-
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
4/8/2024
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”) today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association (JAMA).
-
U.S. Cell Therapy Market Size to Hit USD 19.67 Billion By 2033
4/8/2024
The global U.S. cell therapy market size was valued at USD 2.88 billion in 2023 and is poised to grow from USD 3.49 billion in 2024 to USD 19.67 billion by 2033, growing at a CAGR of 21.18% in the forecast period (2024-2033).
-
Model N to be Acquired by Vista Equity Partners For $1.25 Billion
4/8/2024
Model N announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners, a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.
-
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
4/8/2024
Ascentage Pharma announced that it releases the latest results from three preclinical studies of its novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development inhibitor APG-5918, at the 2024 American Association of Cancer Research Annual Meeting.
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
4/6/2024
AstraZeneca and Daiichi Sankyo's ENHERTU® has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
-
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
4/6/2024
Daiichi Sankyo and AstraZeneca’s ENHERTU® has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
-
Following disappointing Phase III results in less aggressive non-small cell lung cancer, AstraZeneca on Friday announced that Imfinzi improved progression-free and overall survival in patients with limited-stage small cell lung cancer.
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
4/5/2024
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy compared to placebo after cCRT.
-
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
4/5/2024
Innate Pharma SA announced the filing of its 2023 Universal Registration Document for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” on April 4, 2024.
-
The American Association for Cancer Research has invited drug developers and investors to intermingle with the academics who typically attend its annual conference.
-
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
4/4/2024
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
-
MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth
4/4/2024
MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European
-
Oncology Clinical Trials Market Experiencing Rapid Growth
4/4/2024
The global oncology clinical trials market size was valued at USD 13.19 billion in 2023 and is projected to reach USD 22.11 Billion by 2033, growing at a CAGR of 5.3 % from 2024 to 2033. North America dominated the market and accounted for the largest revenue share of 43% in 2023.
-
Congress and the Biden administration have set their sights on lowering prescription drug costs.
-
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033
4/3/2024
According to the latest research by Nova One Advisor, the global biotechnology market size was valued at USD 1.54 Trillion in 2023 and is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% from 2024 to 2033
-
Compugen to Participate in Two Upcoming April 2024 Investor Conferences
4/3/2024
Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that management will participate in the following upcoming investor conferences in April.